The Indian cancer treatment landscape is experiencing a serious crisis as essential chemotherapy medications become increasingly scarce. Hospitals and cancer centres are facing severe disruptions due to this shortage, prompting the government to allow price hikes for certain critical cancer drugs. This measure is intended to restore supply, yet it simultaneously raises concerns about the financial burden on patients who are already coping with the expenses of a complex illness.

Platinum-based chemotherapy drugs, including cisplatin and carboplatin, are at the centre of this crisis. These medications are vital for treating various types of cancer, such as lung, ovarian, cervical, head and neck, bladder, and gastrointestinal cancers. Medical professionals report that these drugs remain among the most effective options available for many solid tumours, with few alternatives at hand.

The National Pharmaceutical Pricing Authority (NPPA) has also sanctioned higher maximum retail prices for two anti-tetanus vaccines. This decision was made following approval from the Union government’s department of pharmaceuticals (DOP). The approval comes amid rising production costs that companies attribute to various factors, including the conflict involving the US and Iran, which is linked to the Hormuz crisis.

Industry Response to Production Costs

Despite the recent approval for price increases, only four medications have received this permission after consultations among various ministries. The Indian drug market includes around 387 medicines and approximately 1,000 formulations across 27 therapeutic categories that are classified as scheduled drugs. Each of these medicines has a Maximum Retail Price (MRP) set by the government annually. Industry insiders noted that drug manufacturers had sought price revisions for a total of 82 medications, citing substantial increases in production costs.

A representative from the Indian Drug Manufacturing Association (IDMA), a prominent organisation of generic drug producers, explained the challenges faced by manufacturers. They highlighted that when production costs rise significantly while MRPs remain low, companies are compelled to decrease manufacturing volumes to mitigate losses. This situation is reportedly contributing to the current shortages experienced in the market.

In the last few months, the scarcity of these essential treatments has intensified, forcing hospitals to ration their supplies and delay treatment schedules. Medical facilities have started to pursue emergency procurement options, while patients and their families find themselves in desperate searches across different cities and states for doses that were previously easily accessible.

Potential Impact on Patient Care

Concerns regarding the availability of treatments have also been raised by the Tata Memorial Centre in Mumbai, India’s leading cancer institute. Experts attribute the supply issues to a significant increase in the cost of platinum, an essential raw material for the production of these drugs. Over the past year, platinum prices have soared, while manufacturers face government-imposed price caps that restrict their ability to adjust prices in accordance with rising input costs.

The situation remains complex and precarious as the healthcare sector navigates these challenges. The government’s recent price approvals may provide some immediate relief, but the overarching issues of affordability and supply continuity continue to loom large over Indian cancer treatment protocols.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share